CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
LY2409021 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01640834
NCT01640834Phase 1Completed
CompareCT.gov

Pilot Study of the Effects of LY2409021 in Patients With Type 1 Diabetes Mellitus

Eli Lilly and Company·interventional·Posted Jul 16, 2012·Updated Oct 29, 2018

In Brief

A Phase 1 clinical trial evaluating LY2409021, Placebo, and 1 other intervention for Diabetes Mellitus, Type 1. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or placebo (an inactive medicine) taken as up to 3 capsules by mouth. The study will evaluate if this drug will reduce the amount of insulin a type 1 diabetic needs over 24 hours. This study includes a 7-day hospitalization period at the clinical research unit (CRU) and will involve screening within 30 days of the start of the study as well as telephone consultations within 5 days after discharge from the CRU.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 16, 2012
Enrollment StartJul 1, 2012
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.0 years ago

Interventions

LY2409021drug

Administered orally

Placebodrug

Administered orally

Glucagondrug

Administered via intramuscular injection